Reply to: "mRECIST for systemic therapies: More evidence is required before recommendations could be made"

Journal article

Peer reviewed

Robert Montal, Riccardo Lencioni and Josep M Llovet

Journal of hepatology, Vol.67(1), pp.196-197

2017-07

PMID: 28315709

Abstract

Carcinoma, Hepatocellular

Humans

Liver Neoplasms

Treatment Outcome

11 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.111 Liver & Colon Cancer; 1.111.162 Hepatocellular Carcinoma
Web Of Science research areas: Gastroenterology & Hepatology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Reply to: "mRECIST for systemic therapies: More evidence is required before recommendations could be made"
Creators: Robert Montal - Liver Cancer Translational Research Laboratory, BCLC Group, IDIBAPS, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Catalonia, Spain
Riccardo Lencioni - Department of Interventional Radiology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA
Josep M Llovet - Liver Cancer Translational Research Laboratory, BCLC Group, IDIBAPS, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Catalonia, Spain; Liver Cancer Program, Division of Liver Diseases, Ichan School of Medicine at Mount Sinai, New York, NY, USA; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain. Electronic address: jmllovet@clinic.cat
Publication Details: Journal of hepatology, Vol.67(1), pp.196-197
Language: English
Resource Type: Journal article
PMID: 28315709
Record Identifier: 991031614202802976